# CEO Strategic Review — Health Insights
**Date:** 2026-05-04
**Author:** CEO Agent
**Audience:** Founder (solo developer)
**Status:** First formal strategic review — post-Sprint 2, pre-feature work

---

## Executive Summary

The foundation is technically solid and sequenced correctly. The CI/CD infrastructure and multi-module architecture are the right investments to make before writing a single line of feature code. However, two compliance blockers — LGPD consent copy and the privacy policy draft — are unfinished and are the only things standing between the current state and Phase 2 (Onboarding). This is the active risk. Everything else is either done or appropriately deferred.

The team is moving in the right order. The next action is clear.

---

## 1. Strategic Alignment

**Finding: Strong alignment. No drift detected.**

The decisions made in Sprints 1 and 2 map directly to the product mission: transform Samsung Health / Health Connect data into actionable insights, on-device, with user trust as a core differentiator.

Specific validations:

- **MVVM + Clean Architecture + multi-module** — the right call for a health data app at this stage. Clean separation of `core/domain` as a pure Kotlin JVM module means business logic is testable without Android instrumentation. This is not over-engineering; it is the minimum architecture that prevents a rewrite when the app scales beyond a single screen.

- **Room + SQLCipher (planned)** — correct. Health data is a special category under LGPD Art. 11. Encrypted at rest from v1 is non-negotiable, and the architecture already anticipates this in `core/database`.

- **Health Connect over Samsung Health SDK direct** — not yet confirmed in Sprint 2, but the module `feature/health-connect` signals this direction. Health Connect is the right call: it is Google's unified health data API, it is required for Play Store health data policy compliance, and it avoids a hard Samsung-only lock-in. The CTO agent should confirm this as the integration target before any SDK work begins.

- **CI as the quality gate on a solo project** — smart leverage. With no code reviewers, automated lint + test + build is the discipline mechanism. The investment is already paying for itself.

**One concern on alignment:** The product mission says "turn raw data into actionable insights," but the current backlog does not yet define what "actionable" means for the first user-facing milestone. The dashboard and insights modules exist as scaffolding, but there is no product spec for what insight v1 looks like. This is acceptable at the current stage — it would be premature to spec it now — but it must be defined before Phase 3 (Dashboard) begins.

---

## 2. Sequencing Assessment

**Finding: Sequence is correct. One gap requires immediate attention.**

The phase ordering is right:

```
Foundation (infra + compliance) → Onboarding (consent + Health Connect) → Dashboard → Insights
```

This is the only safe order for a health data app. You cannot build onboarding without finalizing consent copy (LGPD requires explicit, informed consent before any health data access). You cannot build the dashboard without onboarding. The dependency chain is correctly modeled.

**The gap:** The two compliance items from Phase 1 — LGPD consent copy and privacy policy draft — are marked not started. These are not optional polish items. They are legal prerequisites for the onboarding flow. If onboarding is built without finalized consent language, the flow will be rebuilt. That is wasted effort.

**Sequencing risk: Low overall, but the compliance items are the single-point blocker for all downstream phases.** Until they are done, Phase 2 cannot start without accruing rework debt.

**What is sequenced correctly that deserves recognition:**

- KSP over KAPT — AGP 9.x compatibility issue was caught early. Fixing this in Sprint 2 rather than mid-feature development avoided a painful migration later.
- Hilt 2.59.2 upgrade driven by AGP 9.x incompatibility — same pattern. Dependency management resolved during infrastructure sprints, not feature sprints.
- Branch protection + CI gate before any feature branches — the team will never merge broken code into `main`. This matters more on a solo project where the developer is both author and the only reviewer.

---

## 3. What Must Happen Next, and Why

**Priority 1 (blocking): Close the Phase 1 compliance gap.**

**Decision:** Complete LGPD consent copy and privacy policy draft before starting any Phase 2 (Onboarding) work.

**Rationale:**
- Consent copy is embedded in the onboarding UI. Building onboarding without it means building the flow twice.
- The privacy policy must exist before the app is listed on the Play Store. Starting it now costs less than rushing it at submission time.
- LGPD Art. 11 (health data as sensitive category) requires explicit, purpose-specific consent. The language must be reviewed by someone with LGPD knowledge — the CISO agent should lead this, with the founder reviewing the final copy.
- Google Play's health data policy requires a privacy policy link at submission. This is not optional.

**Trade-offs:** Delaying Phase 2 by the time it takes to produce these documents. This is the correct trade-off. The alternative — building onboarding with placeholder consent text — creates legal and submission risk.

**Next step:** Assign the CISO agent to draft the consent copy and privacy policy. The founder reviews and approves. Target: both complete before the first commit to `feature/onboarding`.

---

**Priority 2 (parallel, non-blocking): Define the v1 insight.**

Before Phase 3 (Dashboard) begins, the CPO agent needs to answer one question: what is the single most valuable insight Health Insights can surface in v1?

Candidates (not a directive — this is the CPO's job):
- "Your sleep consistency score this week vs. your 30-day average"
- "You hit your step goal X of 7 days — your best streak was Y"
- "Your resting heart rate trend over 30 days"

The answer determines what Health Connect data permissions are requested (minimum necessary collection principle), what the dashboard layout is, and what the first onboarding permission screen asks for. Defining this in parallel with the compliance work costs nothing and unblocks Phase 3 the moment Phase 2 completes.

---

**Priority 3 (medium-term): Confirm Health Connect as the sole data integration target.**

The CTO agent must formally confirm whether `feature/health-connect` means Health Connect API only, or whether Samsung Health SDK is also in scope. This decision affects:
- Which data types are accessible (Health Connect has broader OEM coverage; Samsung Health SDK has deeper Samsung-specific data)
- Play Store data declaration requirements
- The dependency surface in `core/data`

This does not block Phase 2, but it must be resolved before `feature/health-connect` has any implementation code.

---

## 4. Risks and Concerns

### Risk 1 — LGPD compliance is a hard gate, not a best-effort item (HIGH)
Health data under LGPD Art. 11 is a sensitive personal data category. Collecting or processing it without explicit consent is not a compliance gap — it is a legal violation. The consent flow must be built correctly from v1. There is no "fix it after launch" option here. The CISO agent must be in the loop on every decision that touches consent flow design, data retention, and subject rights (view, export, delete).

**Status:** Unmitigated. Requires immediate action (see Priority 1 above).

### Risk 2 — No defined target user (MEDIUM)
The product mission is clear, but the target user is not defined. "People who use Samsung Health" is too broad to make good prioritization decisions. A 25-year-old runner optimizing training load and a 55-year-old monitoring post-cardiac-event recovery data need fundamentally different insights, different consent language, and different UX. The CMO agent needs to define a primary persona before Phase 3. This is not blocking Phase 2, but it will create churn in Phase 3 if unresolved.

### Risk 3 — Solo developer bus factor (LOW for now, monitor)
One developer owns the entire stack. This is normal for this stage and is not an action item today. It becomes relevant at two points: (a) if the founder becomes unavailable for an extended period — release signing credentials should be documented and recoverable, and (b) if the app reaches a user base where response time to a data breach matters. The keystore secrets are in GitHub — confirm they are also backed up in a second secure location.

### Risk 4 — Feature scope temptation (LOW, pre-emptive)
The module structure is comprehensive: `feature/workouts`, `feature/sleep`, `feature/insights`, `feature/settings`, `feature/onboarding`, `feature/dashboard`, `feature/health-connect`. This is the right architecture. The risk is treating the existence of these modules as a commitment to build all of them in v1. They do not all need to ship together. A v1 with onboarding + one high-value insight + a minimal dashboard is a better first release than a feature-complete v0.5. The CPO and CEO agents will enforce this when Phase 3 planning begins.

---

## 5. State of the Business

| Dimension | Status | Note |
|---|---|---|
| Infrastructure | Done | CI/CD, branch protection, keystore |
| Architecture | Done | Multi-module, correct layering |
| Compliance (Phase 1) | Blocked | Consent copy + privacy policy not started |
| Onboarding (Phase 2) | Not started | Blocked on compliance |
| Dashboard (Phase 3) | Not started | Awaiting Phase 2 |
| Insights (Phase 4+) | Not started | Awaiting Phase 3 |
| Target persona | Undefined | Needed before Phase 3 |
| v1 insight definition | Undefined | Needed before Phase 3 |
| Data integration target | Unconfirmed | Health Connect vs. Samsung Health SDK |

---

## 6. Summary Directive

**Do this, in this order:**

1. CISO agent drafts LGPD consent copy and privacy policy. Founder reviews and approves. This is the only active blocker.
2. CPO agent defines the v1 insight. One screen, one insight, one data type. Do this in parallel with item 1.
3. CTO agent confirms Health Connect as the sole integration target. One-sentence decision, documented.
4. Start Phase 2 (Onboarding) only after items 1 and 3 are complete.

Nothing else needs a decision today.

---

*CEO Agent — Health Insights | Review period: Sprint 1–2 | Next review: Post-Phase 2 completion*
